Terumo Microtech's IPO on the Sci-Tech innovation board has been approved by the listing committee. Its core product, Stateudata monoclonal antibody injection, has been approved for listing in China.
Zhuhai Tainuo Maibo Pharmaceutical Co., Ltd. passed the listing committee meeting of the SSE STAR Market. Huatai United Securities is the sponsor institution and plans to raise 1.5 billion yuan.
On April 3rd, Zhuhai Tianomab Pharmaceuticals Co., Ltd. (referred to as Tianomab) passed the listing committee meeting of the Shanghai Stock Exchange Sci-Tech Innovation Board. Huatai United Securities is the sponsor institution, aiming to raise 1.5 billion yuan.
According to the prospectus, Tianomab is an innovative biopharmaceutical company dedicated to the development of blood product substitution therapies for the global market. The company is focused on the development, manufacturing, commercialization, and potential replacement of global specific blood products, in order to meet a wide range of clinical needs and benefit patients.
Specifically, the company's core product is the Stedutronab monoclonal antibody injection (recombinant anti-tetanus toxin human monoclonal antibody TNM002, trade name: Xin Tituo, hereinafter referred to as "Stedutronab monoclonal antibody injection" or "TNM002"), which was approved for market in China in February 2025, making it the first global recombinant anti-tetanus toxin monoclonal antibody drug of its kind, recognized by China's CDE as a breakthrough therapy drug and included in the priority review program (also the first domestically innovative biopharmaceutical drug in the field of anti-infectives to be recognized as a breakthrough therapy drug) and included in the U.S. FDA's Fast Track qualification, with globally leading innovative significance in the field of tetanus prevention. The company's other core product, recombinant anti-respiratory syncytial virus human monoclonal antibody TNM001 (hereinafter referred to as "TNM001"), has been submitted for NDA for non-high-risk and high-risk infants and has been accepted, while also being included in the priority review program.
Financially, in the fiscal years 2024 and 2025, Tianomab achieved operating revenues of 15.06 million yuan and 51.22 million yuan respectively; during the same period, the net profits were approximately -515 million yuan and -601 million yuan respectively.
Related Articles
Lei Dao L80 pre-sale orders exceeded the same period as last year's L90, with Nio Hong Kong stocks leading the rise in the Hang Seng Technology Index.
HK Stock Market Move | JIANGXI COPPER (00358) rose over 4% in the afternoon, with a year-on-year increase of more than 40% in net profit attributable to mother in the first quarter. Citi expects the smelting business to remain profitable.
HK Stock Market Move | GEELY AUTO (00175) surged more than 5% in the afternoon, with first quarter revenue surpassing 80 billion yuan and core net profit attributable to shareholders increasing by over 30%.
Lei Dao L80 pre-sale orders exceeded the same period as last year's L90, with Nio Hong Kong stocks leading the rise in the Hang Seng Technology Index.
HK Stock Market Move | JIANGXI COPPER (00358) rose over 4% in the afternoon, with a year-on-year increase of more than 40% in net profit attributable to mother in the first quarter. Citi expects the smelting business to remain profitable.
HK Stock Market Move | GEELY AUTO (00175) surged more than 5% in the afternoon, with first quarter revenue surpassing 80 billion yuan and core net profit attributable to shareholders increasing by over 30%.
